Leverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas.
TACE using QS-GMP may reduce tumor volume and improve clinical signs in dogs with lower urinary tract carcinomas, but further studies are needed to confirm these findings.
Where it sits
this study against the rest of the dihexa corpusSummary and findings
This study evaluated the safety, feasibility, and therapeutic efficacy of transarterial chemoembolization (TACE) using quick-soluble gelatin microparticles (QS-GMP) in 29 client-owned dogs with lower urinary tract carcinomas. A median tumor volume reduction of 76.41% was observed, with partial remission in 96.5% of patients. The median survival time was reported as 569 days for all patients.
Abstract
Lower urinary tract carcinomas in dogs are rare conditions with a poor prognosis. This prospective clinical study evaluated the safety, feasibility, and therapeutic efficacy of transarterial chemoembolization (TACE) using quick-soluble gelatin microparticles (QS-GMP) in 29 client-owned dogs with lower urinary tract carcinomas. Tumors primarily involved the bladder and urethra. Following selective catheterization of tumor-feeding vessels, intra-arterial carboplatin was administered prior to QS-GMP embolization. All patients underwent follow-up computed tomography (CT) scanning 4 weeks post-TACE. Tumor volume decreased in all cases, with a median reduction of 76.41% (95% confidence interval: 65.06-78.41%, <i>p</i> < 0.001). Partial remission was observed in 96.5% of patients; one case showed stable disease. Clinical signs, including pollakiuria, hematuria and stranguria, improved. No major complications occurred during the procedure or within two weeks after the procedure, and minor adverse effects were self-limiting. Repeat TACE was performed in 28/29 patients. The median survival time was 569 days for all patients and 534 days when non-tumor-related deaths were excluded. These findings suggest that TACE with QS-GMP may be an option for dogs with unresectable lower urinary tract carcinomas, with potential for repeated interventions and prolonged survival.
Background
Lower urinary tract carcinomas in dogs are rare and typically have a poor prognosis. Previous treatments have had limited efficacy, and there is a need for novel therapeutic approaches. This study investigates the use of transarterial chemoembolization (TACE) with quick-soluble gelatin microparticles (QS-GMP) as a potential treatment option.
Methods
This was a prospective clinical study involving 29 client-owned dogs diagnosed with lower urinary tract carcinomas. The study involved selective catheterization of tumor-feeding vessels, followed by intra-arterial administration of carboplatin and QS-GMP embolization. Follow-up computed tomography (CT) scans were performed 4 weeks post-TACE to assess tumor response.
Results
The primary endpoint showed a median tumor volume reduction of 76.41% (95% CI: 65.06-78.41%, p<0.001). Partial remission was observed in 96.5% of patients, with one case showing stable disease. Clinical signs such as pollakiuria, hematuria, and stranguria improved in the majority of cases. No major complications were reported during or after the procedure.
Interpretation
The findings suggest that TACE with QS-GMP may provide significant tumor reduction and improvement in clinical signs. However, the effect size, while statistically significant, may not be clinically meaningful for all patients. The small sample size and lack of long-term follow-up limit the generalizability of the results.
Key findings
- Median tumor volume reduction of 76.41% (95% CI: 65.06-78.41%, p<0.001).
- Partial remission observed in 96.5% of patients; one case showed stable disease.
- No major complications occurred during the procedure or within two weeks after the procedure.
- Median survival time was 569 days for all patients.
- Median survival time was 534 days when non-tumor-related deaths were excluded.
Limitations
- Small sample size of 29 dogs.
- Short follow-up period of 4 weeks post-treatment.
- Not reported in abstract.